
Apr 28, 2026
AI start-up Profluent nabs Lilly as first big pharma partner
AI start-up Profluent has formed a significant partnership with Eli Lilly, valued at up to $2.25 billion, to advance gene-editing therapies. Founded in 2022, Profluent has garnered attention for its innovative technology that enables the insertion of entire genes into DNA, surpassing the localized editing capabilities of methods like CRISPR/Cas9. This collaboration aims to leverage Profluent's AI models for developing recombinase editors that can insert extensive DNA sequences at specific genomi

